Health Care • Biotechnology: Pharmaceutical Preparations
$0.52 ▼ -0.01
(-1.49%)
MKT CAP: $21.2M • VOL: 31.1K
52W L $0 52W H $2
ROARABLE / RQD
D- • 42/100
PIOTROSKI
2 / 9
BYSI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$8.9M | -$8.8M | -$15.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$1.0M | -$11.1M | -$21.0M |
| EBITDA (Normalized) | -$8.9M | -$8.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$19.8M | -$16.4M | -$16.5M |
| Capital Expenditures (CapEx) | $50.0K | $224.0K | — |
| Free Cash Flow (FCF) | -$19.8M | -$16.7M | -$16.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $7.8M | $2.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$32.2M | -$32.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BYSI.